Extended-Release Melatonin in Patients With Rapid Eye Movement Sleep Behavior Disorder

Randomized, Double-Blind, Cross-Over Study Comparing the Efficacy of Immediate and Extended-Release Melatonin as a Supplement Affecting the Sleep Cycle in Patients With Parkinson Disease and Rapid Eye Movement Sleep Behavior Disorder

The purpose of this research is to compare the efficacy of immediate versus extended-release melatonin as a supplement affecting the sleep cycle in patients with Parkinson disease and Rapid Eye Movement Sleep Behavior Disorder.

Enrolled patients with Parkinson disease and previously diagnosed rapid eye movement sleep behavior disorder, who are being treated at Mayo Clinic in Florida, will be randomized to receive either immediate-release melatonin or extended-release melatonin and then will be crossed over to receive the opposite intervention. The study will consist of two treatment periods of 4 weeks separated by a washout period of 2 weeks.

Inclusion Criteria:

• Diagnosed with Parkinson's disease and rapid eye movement sleep behavior disorder.
• Patient registered to Parkinson's disease database of Mayo Clinic Florida.

Exclusion Criteria:

• Patients who are using other sleep aids or medications (Clonazepam).
• Patients who are not willing to undertake 1 week of washout period.
• Patients who do not sign a consent for research.